Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
### Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
### Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose every week based on response and tolerability, not to exceed 20 mg twice daily.
* **Maintenance:** Typically 10-20 mg twice daily. Maximum recommended daily dose is 40 mg.
### Pediatric Dosing (2 to <10 years of age or <30 kg)
* **Initiation:** 2.5 mg once daily.
* **Titration:** Increase dose every week based on response and tolerability, typically by 2.5 mg to 5 mg every week.
* **Maintenance:** Doses of 5 mg twice daily are common. Maximum recommended daily dose is 20 mg.
### Pediatric Dosing (10 years of age and older or ≥30 kg)
* Follow adult dosing recommendations.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider lower starting doses and slower titration.
* **Renal Impairment:** Use with caution. Consider lower starting doses and slower titration.
* **Concomitant Medications:** Consider interactions (see Key Drug Interactions).
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Acute narrow-angle glaucoma.
### Adverse Effects
Common: Somnolence, decreased appetite, aggression, irritability, constipation, cough, upper respiratory tract infection, ataxia, difficulty with coordination, vomiting.
Serious: Suicidal ideation, withdrawal symptoms (seizures, rebound insomnia, anxiety), respiratory depression, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis).
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **Other Antiepileptic Drugs (AEDs):** Potential for additive CNS depression. Monitor for increased sedation and neurotoxicity.
### Monitoring
* Signs of efficacy (seizure frequency).
* Signs of CNS depression (somnolence, dizziness, impaired coordination).
* Behavioral changes (e.g., suicidal ideation, aggression).
* Signs of withdrawal upon discontinuation.
* Liver and kidney function, particularly with prolonged use or in patients with pre-existing impairment.
### Clinical Pearls
* Clobazam is generally less sedating than other benzodiazepines, but somnolence is still a common side effect.
* Withdrawal symptoms can be severe; taper dose gradually if discontinuing therapy.
* Monitor for the development of suicidal behavior or thoughts.
* Onset of tolerance may occur with prolonged use.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
